Saturday, 31 October 2026European Markets

KBC ANCORA And REINET INVESTMENTS Have A High Dividend Yield And Return On Equity In The Asset Management Industry.

Loading stream...

(VIANEWS) - KBC ANCORA (KBCA.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Asset Management industry.

Financial Asset Price Forward Dividend Yield Return on Equity
KBC ANCORA (KBCA.BR) €46.25 21.61% 8.57%
REINET INVESTMENTS (REINA.AS) €22.80 1.28% 4.16%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. KBC ANCORA (KBCA.BR)

21.61% Forward Dividend Yield and 8.57% Return On Equity

KBC Ancora SCA holds participating interest in KBC Group SA. The company was formerly known as Almancora SCA and changed its name to KBC Ancora SCA in June 2007. KBC Ancora SCA was incorporated in 1998 and is based in Leuven, Belgium. KBC Ancora SCA is a subsidiary of Cera SC.

Earnings Per Share

As for profitability, KBC ANCORA has a trailing twelve months EPS of €3.91.

PE Ratio

KBC ANCORA has a trailing twelve months price to earnings ratio of 11.83. Meaning, the purchaser of the share is investing €11.83 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.57%.

More news about KBC ANCORA.

2. REINET INVESTMENTS (REINA.AS)

1.28% Forward Dividend Yield and 4.16% Return On Equity

Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg City, Luxembourg.

Earnings Per Share

As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €1.25.

PE Ratio

REINET INVESTMENTS has a trailing twelve months price to earnings ratio of 18.24. Meaning, the purchaser of the share is investing €18.24 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.16%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, REINET INVESTMENTS's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for REINET INVESTMENTS is 580 which is 6.3% below its average volume of 619.

More news about REINET INVESTMENTS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com